BRPI0620063A8 - formulação de liberação controlada que compreende octreotídeo e dois ou mais polímeros de polilactídeo-co-glicolídeo - Google Patents

formulação de liberação controlada que compreende octreotídeo e dois ou mais polímeros de polilactídeo-co-glicolídeo

Info

Publication number
BRPI0620063A8
BRPI0620063A8 BRPI0620063A BRPI0620063A BRPI0620063A8 BR PI0620063 A8 BRPI0620063 A8 BR PI0620063A8 BR PI0620063 A BRPI0620063 A BR PI0620063A BR PI0620063 A BRPI0620063 A BR PI0620063A BR PI0620063 A8 BRPI0620063 A8 BR PI0620063A8
Authority
BR
Brazil
Prior art keywords
octreotide
polylactide
controlled release
release formulation
glycolide polymers
Prior art date
Application number
BRPI0620063A
Other languages
English (en)
Inventor
Petersen Holger
Ahlheim Markus
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37772904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0620063(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0526247A external-priority patent/GB0526247D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to BR122019027412A priority Critical patent/BR122019027412B8/pt
Publication of BRPI0620063A2 publication Critical patent/BRPI0620063A2/pt
Publication of BRPI0620063A8 publication Critical patent/BRPI0620063A8/pt
Publication of BRPI0620063B1 publication Critical patent/BRPI0620063B1/pt
Publication of BRPI0620063B8 publication Critical patent/BRPI0620063B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Peptides Or Proteins (AREA)
  • Polyesters Or Polycarbonates (AREA)

Abstract

formulação de liberação controlada que compreende octreotídeo e dois ou mais polímeros de polilactídeo-co-glicolídeo, uso, processo de fabricação de micropartículas e kit. a presente invenção refere-se às formulações de liberação con- trolada compreendendo como ingrediente ativo octreotideo ou um sal farma- ceuticamente aceitável do mesmo e dois ou mais polímeros de polilactideo- co-glicol ideo (plgas) diferentes.
BRPI0620063A 2005-12-22 2006-12-20 composição farmacêutica de liberação sustentada na forma de micropartículas, uso, e kit de administração BRPI0620063B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019027412A BR122019027412B8 (pt) 2005-12-22 2006-12-20 composição farmacêutica de liberação sustentada na forma de micropartículas, processo para preparação das ditas micropartículas, e kit de administração

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0526247A GB0526247D0 (en) 2005-12-22 2005-12-22 Organic compounds
GB05262477.2 2005-12-22
GB0526247.2 2005-12-22
EP06119086.4 2006-08-17
EP06119086 2006-08-17
PCT/EP2006/012313 WO2007071395A1 (en) 2005-12-22 2006-12-20 Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers

Publications (4)

Publication Number Publication Date
BRPI0620063A2 BRPI0620063A2 (pt) 2011-11-01
BRPI0620063A8 true BRPI0620063A8 (pt) 2018-05-02
BRPI0620063B1 BRPI0620063B1 (pt) 2020-09-08
BRPI0620063B8 BRPI0620063B8 (pt) 2021-05-25

Family

ID=37772904

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0620063A BRPI0620063B8 (pt) 2005-12-22 2006-12-20 composição farmacêutica de liberação sustentada na forma de micropartículas, uso, e kit de administração
BR122019027412A BR122019027412B8 (pt) 2005-12-22 2006-12-20 composição farmacêutica de liberação sustentada na forma de micropartículas, processo para preparação das ditas micropartículas, e kit de administração

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122019027412A BR122019027412B8 (pt) 2005-12-22 2006-12-20 composição farmacêutica de liberação sustentada na forma de micropartículas, processo para preparação das ditas micropartículas, e kit de administração

Country Status (22)

Country Link
US (6) US20090004283A1 (pt)
EP (3) EP3603623A1 (pt)
JP (4) JP2009520727A (pt)
KR (5) KR101458728B1 (pt)
CN (1) CN103251929A (pt)
AR (1) AR058591A1 (pt)
AU (1) AU2006328950B2 (pt)
BR (2) BRPI0620063B8 (pt)
CA (1) CA2631811C (pt)
CL (1) CL2018003398A1 (pt)
EC (1) ECSP088560A (pt)
ES (2) ES2755032T3 (pt)
IL (1) IL191842A0 (pt)
IN (1) IN2015DN03936A (pt)
MA (1) MA30064B1 (pt)
NO (1) NO20082988L (pt)
PE (1) PE20071139A1 (pt)
PL (2) PL1968549T3 (pt)
PT (2) PT2359809T (pt)
RU (1) RU2464972C2 (pt)
TW (2) TWI468172B (pt)
WO (1) WO2007071395A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99830C2 (uk) 2007-06-06 2012-10-10 Дебио Ресшерчи Фармасютикю С.А. Фармацевтична композиція з пролонгованим вивільненням, виготовлена з мікрочастинок
US8470360B2 (en) * 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
ES2324009B1 (es) * 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
AU2013201877B2 (en) * 2008-01-30 2015-01-29 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
KR101921800B1 (ko) 2008-01-30 2018-11-23 노파르티스 아게 옥트레오티드 및 3종의 선형 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
AU2015201581B2 (en) * 2008-09-17 2017-03-09 Amryt Endo, Inc. Pharmaceutical Compositions and Related Methods of Delivery
WO2010032140A2 (en) * 2008-09-17 2010-03-25 Chiasma Inc. Pharmaceutical compositions and related methods of delivery
US20100151033A1 (en) * 2008-12-15 2010-06-17 Novartis Ag Octreotide depot formulation with constantly high exposure levels
WO2010085609A2 (en) * 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Controlled release systems from polymer blends
EP2595604B1 (en) * 2010-07-21 2016-03-30 Allergan, Inc. Method of controlling initial drug release of sirna from sustained-release implants
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
WO2012083026A1 (en) * 2010-12-15 2012-06-21 Evonik Degussa Corporation Branched polyol polyesters, blends and pharmaceutical formulations comprising same
BR112013027235B1 (pt) * 2011-04-25 2021-11-16 Shan Dong Luye Pharmaceutical Co., Ltd Composição farmacêutica, seu uso, e formulação de microsferas para injeção de liberação sustentada
CN102488619B (zh) * 2011-12-05 2014-08-06 上海交通大学 连续生产艾塞那肽微球的装置及控制微球释放速度的方法
MA41462A (fr) 2015-02-03 2021-05-12 Chiasma Inc Méthode de traitement de maladies
JP6165356B2 (ja) * 2015-06-26 2017-07-19 オリンパス株式会社 内視鏡システム
US20220000782A1 (en) * 2016-12-27 2022-01-06 Upexmed Co. Ltd. Prevention of local tumor recurrence following surgery using sustainedand/or delayed release of medicaments contained in micro-particles
KR102142026B1 (ko) * 2017-05-31 2020-08-06 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법
CN111214643A (zh) * 2020-03-11 2020-06-02 苏州善湾生物医药科技有限公司 一种基于皮下凝胶缓释的奥曲肽组合物、制备方法及应用
KR20220163416A (ko) * 2020-05-08 2022-12-09 엠. 테크닉 가부시키가이샤 생리 활성 물질이 균일하게 분산된 마이크로스피어 및 그것을 함유하는 서방성 제제
JP6792900B1 (ja) * 2020-05-08 2020-12-02 エム・テクニック株式会社 生理活性物質が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤
CN114174385B (zh) 2020-05-08 2023-03-14 M技术株式会社 主剂均匀分散的微球和含有其的缓释制剂
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CY1327A (en) 1979-11-27 1986-06-27 Sandoz Ag Novel polypeptides,processes for their production,pharmaceutical compositions comprising said polypeptides and their use
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5470582A (en) * 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
KR100260632B1 (ko) * 1992-12-28 2000-07-01 성재갑 이식형 소마토트로핀 조성물
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US6447796B1 (en) * 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
WO1998027980A2 (en) * 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
AR012448A1 (es) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
AU742372B2 (en) * 1997-06-04 2002-01-03 Debio Recherche Pharmaceutique S.A. Implants for controlled release of pharmaceutically active principles and method for making same
ES2169980B1 (es) * 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
KR100392501B1 (ko) * 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
ES2292655T3 (es) * 2002-03-15 2008-03-16 Alrise Biosystems Gmbh Microparticulas y procedimiento para su preparacion.
NZ539810A (en) * 2002-11-06 2008-03-28 Alza Corp Controlled release injectable depot formulations
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
KR100466637B1 (ko) * 2003-06-26 2005-01-13 주식회사 펩트론 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법
JP2008518881A (ja) * 2003-07-18 2008-06-05 オークウッド ラボラトリーズ，エル．エル．シー． 高分子組成物中の高分子の分子量低下、不純物形成およびゲル化の防止
WO2005009357A2 (en) * 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
AU2005271242B9 (en) * 2004-08-12 2012-04-12 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical compositions for controlled release delivery of biologically active compounds

Also Published As

Publication number Publication date
EP1968549B1 (en) 2014-05-14
EP3603623A1 (en) 2020-02-05
PE20071139A1 (es) 2007-11-16
TWI468172B (zh) 2015-01-11
RU2464972C2 (ru) 2012-10-27
RU2008129626A (ru) 2010-01-27
JP2013177406A (ja) 2013-09-09
EP1968549A1 (en) 2008-09-17
EP2359809A1 (en) 2011-08-24
JP6239851B2 (ja) 2017-11-29
AU2006328950B2 (en) 2010-07-29
KR20140133968A (ko) 2014-11-20
KR20130024987A (ko) 2013-03-08
AU2006328950A1 (en) 2007-06-28
BR122019027412B8 (pt) 2021-07-27
ES2492641T3 (es) 2014-09-10
US20150037420A1 (en) 2015-02-05
BRPI0620063B1 (pt) 2020-09-08
PT1968549E (pt) 2014-08-29
IN2015DN03936A (pt) 2015-10-02
MA30064B1 (fr) 2008-12-01
US20090004283A1 (en) 2009-01-01
AR058591A1 (es) 2008-02-13
JP2015044823A (ja) 2015-03-12
JP6178772B2 (ja) 2017-08-09
US20180140662A1 (en) 2018-05-24
US20200206306A1 (en) 2020-07-02
CN103251929A (zh) 2013-08-21
BRPI0620063A2 (pt) 2011-11-01
JP2009520727A (ja) 2009-05-28
JP2016216467A (ja) 2016-12-22
PL2359809T3 (pl) 2020-01-31
EP2359809B1 (en) 2019-08-14
KR101245919B1 (ko) 2013-03-20
IL191842A0 (en) 2008-12-29
TWI469788B (zh) 2015-01-21
KR20130024988A (ko) 2013-03-08
NO20082988L (no) 2008-08-29
KR101458728B1 (ko) 2014-11-05
ES2755032T3 (es) 2020-04-21
ECSP088560A (es) 2008-07-30
TW201424747A (zh) 2014-07-01
WO2007071395A1 (en) 2007-06-28
US20160120935A1 (en) 2016-05-05
BR122019027412B1 (pt) 2020-12-01
KR20130024986A (ko) 2013-03-08
CL2018003398A1 (es) 2019-04-26
BRPI0620063B8 (pt) 2021-05-25
KR20080078000A (ko) 2008-08-26
US20220296675A1 (en) 2022-09-22
TW200803921A (en) 2008-01-16
PL1968549T3 (pl) 2014-10-31
PT2359809T (pt) 2019-11-04
CA2631811A1 (en) 2007-06-28
CA2631811C (en) 2017-06-20

Similar Documents

Publication Publication Date Title
BRPI0620063A8 (pt) formulação de liberação controlada que compreende octreotídeo e dois ou mais polímeros de polilactídeo-co-glicolídeo
AR052238A1 (es) Formulacion de tabletas estables
HK1141441A1 (en) Sustained release pellets comprising wax-like material
PT2043600T (pt) Formulações farmacêuticas para a libertação prolongada de princípio(s) ativo(s), assim como suas aplicações, nomeadamente terapêuticas
WO2008118133A3 (en) Silk microspheres for encapsulation and controlled release
WO2010079047A3 (en) Octreotide depot formulation with constantly high exposure levels
MX2019012598A (es) Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
WO2006130607A3 (en) Controlled-release formulation useful for treating disorders associated with hepatitis c virus
WO2009072007A3 (en) Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
PT2076119E (pt) Composição solvente incluindo pelo menos dois solventes, e formulação fitossanitária que inclua a composição referida bem como um composto activo
WO2010111640A3 (en) Anti-influenza formulations and methods
HK1146465A1 (en) Parathyroid hormone formulations and uses thereof
TR201909277T4 (tr) Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları.
WO2007014124A3 (en) High drug load formulations and dosage forms
MX2010002735A (es) Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
ECSP088203A (es) Dispersiones amorfas sólidas
ATE505187T1 (de) Pharmazeutische zusammensetzung mit verzögerter freisetzung aus tolterodin
MX2010008365A (es) Formulacion de liberacion sostenida que comprende octreotido y tres polimeros lineales de polilactido-co-glicolido.
BRPI0804820A2 (pt) formulações agroquìmicas dispersìveis em água
EP2222271A4 (en) ACTIVE FORMULATIONS BASED ON ESSENTIAL OIL OF PLANTS OF THE GENUS PROTIUM, GUATTERIA, CYPERUS AND A MIXTURE THEREOF
ATE462414T1 (de) Irbesartan enthaltende feste zubereitung
EA201100753A1 (ru) Композиции с пролонгированным высвобождением, содержащие производное 2-оксо-1-пирролидина
WO2007137216A3 (en) Gastroretentive sustained release formulations
TW200727921A (en) Formulation for prolonged release of active ingredients of medicaments

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/12/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF